# Safety, Tolerability and Pharmacokinetics (PK) Investigation of GSK3494245 in Healthy Participants

> **NCT04504435** · PHASE1 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 59 (actual)

## Conditions studied

- Leishmaniasis

## Interventions

- **DRUG:** GSK3494245
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04504435
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-09-29
- **Primary completion:** 2024-01-14
- **Final completion:** 2024-01-14
- **Target enrollment:** 59 (ACTUAL)
- **Why stopped:** Further development of GSK3494245 has been halted based on assessment of clinical data indicating that predicted efficacious doses cannot be achieved in line with dosing requirements outlined in the target product profile for the proposed indication.
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04504435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04504435, "Safety, Tolerability and Pharmacokinetics (PK) Investigation of GSK3494245 in Healthy Participants". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04504435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*